Ionis to Independently Advance Inotersen and IONIS-FB-L Rx

Inotersen on Track for Marketing Authorization Filings This Year Conference Call Webcast Friday, August 11, 8:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Aug. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported that the Company has retained all rights to inotersen and IONIS-FB-LRx. As part of a reprioritization of its pipeline and strategic review of its Rare Diseases business, GSK declined its options on both drugs. Ionis plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018. Inotersen is a drug designed to treat patients with TTR amyloidosis (ATTR). The first indication Ionis is pursuing for inotersen is to treat patients with polyneuropathy due to hereditary TTR amyloidosis (hATTR-PN).

The release as fetched from its publisher. ionis.com ↗